Patent intelligence · US
US 10179912
RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
Patent details — US 10179912
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 15, 2019
- Expiration
- Jan 10, 2039
- Applicant
- BIOMARIN TECHNOLOGIES B.V.
- Claims
- 9
- CPC classes
- A61P, A61P21/00, A61P43/00
Quick answer
US 10179912 (RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy) is held by BIOMARIN TECHNOLOGIES B.V.. Status: granted. Granted Jan 15, 2019. Expires Jan 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOMARIN TECHNOLOGIES B.V.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61P, A61P21/00, A61P43/00
More from BIOMARIN TECHNOLOGIES B.V.
Related pharmaceutical patents in our USPTO index.
-
US 12427171
Krill oil composition enriched in LPC-DHA and LPC-EPA
granted -
US 12331293
Bispecific antisense oligonucleotides for dystrophin exon skipping
granted -
US 12239692
Adeno-associated virus factor VIII vectors
granted -
US 12233106
C-type natriuretic peptide variants to treat skeletal dysplasia in children
granted -
US 12214015
Use of c-type natriuretic peptide variants to treat osteoarthritis
granted -
US 12194064
Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids
granted -
US 12188058
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
granted -
US 12076372
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted
Frequently asked questions
What is US patent 10179912?
US 10179912 (RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy) is held by BIOMARIN TECHNOLOGIES B.V.. Status: granted. Granted Jan 15, 2019. Expires Jan 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10179912?
BIOMARIN TECHNOLOGIES B.V. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 175 pharmaceutical patents for this assignee.
When does US 10179912 expire?
Our index shows an expiration date of Jan 10, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.